This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
by Ahan Chakraborty
Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.
LLYNegative Net Change NVONegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
by Zacks Equity Research
NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.
NVCTNegative Net Change ACIUPositive Net Change AMRXNegative Net Change PGENNegative Net Change
biotechnology
Earnings, Cancer Vaccine, Long-Term Liquidity: A Busy Pre-Market
by Mark Vickery
Q2 retail earnings continue, Moderna sees positive Phase 3 results, and the Treasury lowers the longer-term bond rate.
MRKNegative Net Change TGTNegative Net Change TJXNegative Net Change LOWNegative Net Change ELNegative Net Change MRNAPositive Net Change
biotechnology biotechs cancer earnings finance
Latham Group (SWIM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
SWIMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Docebo Inc. (DCBO) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
DCBOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
by Nalak Das
Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.
ANIKNegative Net Change FETNegative Net Change NESRPositive Net Change OPHCNegative Net Change EDRYNegative Net Change
biotechnology finance oil-energy transportation
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
by Ekta Bagri
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
GILDPositive Net Change GSKNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
by Zacks Equity Research
argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.
ARGXNegative Net Change ACIUPositive Net Change AMRXNegative Net Change PGENNegative Net Change
biotechnology
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
by Zacks Equity Research
United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.
UTHRNegative Net Change RGENPositive Net Change ACIUPositive Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
by Zacks Equity Research
EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
EYPTPositive Net Change REGNNegative Net Change BAYRYPositive Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals